See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

STAT™ Medical Devices

Roger Huckleberry

STAT™ Medical Devices

Stylish and Fashionable Testing Cases

Kyrra Richards

Stylish and Fashionable Testing Cases

Continuous Glucose Monitoring with DEXCOM's

Deb Ruppert

Continuous Glucose Monitoring with DEXCOM's "The Seven"

diabetes medicine

Updated 3 days ago
New Pen Needle Offers Innovative Design
Oct 4, 2014 | 
One of the leading manufacturers of diabetes supplies has released a new pen needle designed to make injecting diabetes drugs a less distressing experience, potentially boosting drug compliance.
When Given Control Over Monitoring And Medication, High-Risk Patients Are Able To Lower Their Blood Pressure
Sep 25, 2014 | 
A new study finds that patients with hypertension who are given control over monitoring their blood pressure as well as making adjustments to their medications are better able to lower their systolic blood pressure than those who use convention treatment.
DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

STAT™ Medical Devices

Roger Huckleberry

STAT™ Medical Devices

Stylish and Fashionable Testing Cases

Kyrra Richards

Stylish and Fashionable Testing Cases

Continuous Glucose Monitoring with DEXCOM's

Deb Ruppert

Continuous Glucose Monitoring with DEXCOM's "The Seven"

Eylea Earns FDA Approval To Treat Diabetic Macular Edema
Sep 3, 2014 | 
The U.S. Food and Drug Administration has approved the eye drug Eylea for the treatment of diabetic macular edema, according to the drug makers Regeneron Pharmaceuticals, Inc.
FDA Lifts Restrictions on Patient Access to Avandia
Aug 7, 2014 | 
The type 2-diabetes drug Avandia will again be available through retail pharmacies after a May ruling by the U.S. Food and Drug Administration.

The drug - a rosiglitazone-based medicine that controls blood glucose by increasing the body’s sensitivity to insulin, so cells and muscles are able to use more for energy, reducing levels in the blood - was off the market in Europe and restricted in the United States for several years due to studies showing the drug raised the risk of heart disease. The FDA in 2013 reversed its earlier opinion and lifted restrictions on the drug, opening the doors for Avandia’s return to market.

Initially released in 1999, Avandia had been one of Glaxo's top-selling medicines, with sales of $3.2 billion in 2006. Sales tanked in 2010 after a review of clinical trials showed an increased risk of heart attack related to the drug – those taking the drug in the United States dropped from 120,000 to 3,000 – but last year, new trials showed no elevated risk of heart attack or death in patients being treated with Avandia compared to other diabetes drugs, causing the FDA to reverse its opinion.

“GSK welcomes the decision of the FDA and appreciates the agency’s robust review of the science about Avandia,” Glaxo said in a statement last year. “GSK maintains its view that Avandia is a safe and effective treatment for Type 2 diabetes when used appropriately.”

While the drug had previously been available only through specialty pharmacies and the patients already taking the drug or whose symptoms were not adequately controlled by other drugs, the new FDA ruling allows all patient's access to Avandia, Avandamet and Avandaryl. All of these medications contain rosiglitazone.

“Our actions reflect the most current scientific knowledge about the risks and benefits of this drug,” Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in a statement last year. “Given these new results, our level of concern is considerably reduced; thus, we require the removal of certain prescribing restrictions.”

While the drug’s manufacturer, GlaxoSmithKline, has a marketing hurdle to overcome given the bad press the drug has received over the last few years, the British drug maker has no plans to promote Avandia in the United States, in part because its U.S. patent protection lapsed in 2011.
The drug will be available by prescription.

To assist in the transition, a toll-free telephone number has been established for patients, healthcare professionals and pharmacies - 1-800-282-6342 – which will be staffed from 8;30 a.m. to 5 p.m. Monday through Friday Eastern Time.
Weekly Dulaglutide Performs Well in Comparison to Daily Liraglutide
Aug 1, 2014 | 
A comparison of the effects on A1c between users of once-weekly dulaglutide (made by Eli Lilly and Company) and once-daily liraglutide (sold as Victoza from Novo Nordisk) shows that both drugs have very similar effects.
What Type 2s Can Do When Blood Sugar Soars
Jul 16, 2014 | 
The emergency condition most type 2s dread is hypoglycemia, where plummeting blood sugar levels can bring on a dangerous semi-conscious state, and even coma or death.
Life With Type 2: Lab Rat
Jul 9, 2014 | 
Since my diagnosis as a type 2 in 2003, I've participated in three Phase 3 drug studies. I am fortunate to live two miles away from one of the San Francisco Bay Area's premier endocrinologists, Dr. Richard Bernstein (who has the same name as the famous low-carb advocate based on Long Island, New York). Over the years, Dr. Bernstein has established his office as a go-to testing facility for drugs in late-stage development.
Next Page »  
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.